NORFLOXACIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H18FN3O3
Molecular Weight	319.3308
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N3CCNCC3

InChI

InChIKey=OGJPXUAPXNRGGI-UHFFFAOYSA-N

InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)

HIDE SMILES / InChI

Molecular Formula	C16H18FN3O3
Molecular Weight	319.3308
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019384s052lbl.pdf
Curator's Comment: description was created based on several sources, including https://davisplus.fadavis.com/3976/meddeck/pdf/norfloxacin.pdf

Norfloxacin is an antibacterial agent, It inhibits inhibits DNA synthesis by inhibiting DNA gyrase enzyme. Norfloxacin was approved in 1986 for treatment of urinary tract infections, gynecological infections, prostatitis, gonorhhea and bladder infections. In ophtalmology, norfloxacin is used for treatment of conjunctivitus.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase II beta 14 Target ID: CHEMBL3396 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2824776	Inhibitor 8228
Topoisomerase IV 62 Target ID: CHEMBL2363076 Sources:

Conditions

Condition	Modality	Highest Phase	Product
Urinary tract infections 204 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019384s052lbl.pdf	Curative	Approved 8360	NOROXIN Approved Use Uncomplicated urinary tract infections (including cystitis) due to Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, Staphylococcus saprophyticus, Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Proteus vulgaris, Staphylococcus aureus, or Streptococcus agalactiae. Complicated urinary tract infections due to Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, or Serratia marcescens. Launch Date 5.31014386E11
Gonorrhea 30 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019384s052lbl.pdf	Curative	Approved 8360	NOROXIN Approved Use Uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae. Launch Date 5.31014386E11
Prostatitis 25 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019384s052lbl.pdf	Curative	Approved 8360	NOROXIN Approved Use Prostatitis due to Escherichia coli Launch Date 5.31014386E11
Conjunctivitis 17 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/19757S10lbl.pdf	Curative	Approved 8360	CHIBROXIN Approved Use CHIBROXIN Ophthalmic Solution is indicated for the treatment of conjunctivitis when caused by susceptible strains of the following bacteria: Acinetobacter calcoaceticus, Aeromonas hydrophila, Haemophilus influenzae, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus Staphylococcus epidermidis, Staphylococcus warnerii, Streptococcus pneumoniae. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of CHIBROXIN Ophthalmic Solution. Launch Date 6.770304E11

C_max

Value	Dose	Co-administered	Analyte	Population
2.02 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019384s067lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		NORFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
9.8 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019384s067lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		NORFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019384s067lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		NORFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
85% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019384s067lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		NORFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1600 mg single, oral Studied dose Dose: 1600 mg Route: oral Route: single Dose: 1600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6220672/	healthy, 24 ± 2 years n = 14 Health Status: healthy Age Group: 24 ± 2 years Sex: M Population Size: 14 Sources: https://pubmed.ncbi.nlm.nih.gov/6220672/	Sources: https://pubmed.ncbi.nlm.nih.gov/6220672/
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1316075	unhealthy, 32 years (range: 18-96 years) n = 357 Health Status: unhealthy Age Group: 32 years (range: 18-96 years) Sex: M+F Population Size: 357 Sources: https://pubmed.ncbi.nlm.nih.gov/1316075	Disc. AE: Nausea, Rash... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Rash (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/1316075
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3158272	unhealthy, 46.0 years n = 190 Health Status: unhealthy Age Group: 46.0 years Sex: M+F Population Size: 190 Sources: https://pubmed.ncbi.nlm.nih.gov/3158272	Disc. AE: Abdominal cramps... AEs leading to discontinuation/dose reduction: Abdominal cramps (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3158272

AEs

AE	Significance	Dose	Population
Nausea	1 patient Disc. AE	400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1316075	unhealthy, 32 years (range: 18-96 years) n = 357 Health Status: unhealthy Age Group: 32 years (range: 18-96 years) Sex: M+F Population Size: 357 Sources: https://pubmed.ncbi.nlm.nih.gov/1316075
Rash	2 patients Disc. AE	400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1316075	unhealthy, 32 years (range: 18-96 years) n = 357 Health Status: unhealthy Age Group: 32 years (range: 18-96 years) Sex: M+F Population Size: 357 Sources: https://pubmed.ncbi.nlm.nih.gov/1316075
Abdominal cramps	1 patient Disc. AE	400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3158272	unhealthy, 46.0 years n = 190 Health Status: unhealthy Age Group: 46.0 years Sex: M+F Population Size: 190 Sources: https://pubmed.ncbi.nlm.nih.gov/3158272

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1579			inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 704 CYP3A2 10 CYP1A2 1509

Drug as perpetrator

Target	Modality	Activity
CYP3A4 1909	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/8894516/	likely
CYP2A6 736	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/14738594/	no
CYP1A2 1673	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC188773/	yes [Inhibition 500 uM]
CYP3A2 13	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/8894516/	yes [Ki 2300 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://pubmed.ncbi.nlm.nih.gov/17027138/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:100246	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:100246
ChemicalBook	CB1711035	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1711035
MolPort	MolPort-001-738-625	https://www.molport.com/shop/molecule-link/MolPort-001-738-625
Selleck Chemicals	Norfloxacin(Norxacin)	http://www.selleckchem.com/products/Norfloxacin(Norxacin).html
ZINC	ZINC000000003742	http://zinc15.docking.org/substances/ZINC000000003742
eMolecules	902214	https://www.emolecules.com/cgi-bin/more?vid=902214

PubMed

Title	Date	PubMed
Norfloxacin in the treatment of uncomplicated gonococcal infections.	1987 Jun 26	3300310
Interaction of fluoroquinolones and certain ionophores in broilers: effect on blood levels and hepatic cytochrome p450 monooxygenase activity.	2001	11791885
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.	2001	11735605
Resistance to antibiotics in injured coliforms isolated from drinking water.	2001	11471826
Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime.	2001	11440218
[Activity of bicozamycin against Escherichia coli O157:H7 producing Vero toxin].	2001	11431931
The concentration of three anti-seizure medications in hair: the effects of hair color, controlling for dose and age.	2001	11339881
Quinolone interactions with DNA and DNA gyrase.	2001	11089230
Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function.	2001 Apr	11316178
Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro.	2001 Aug	11516932
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].	2001 Dec	11856983
Antibiotic failure in the treatment of urinary tract infections in young women.	2001 Dec	11733475
In vitro method for prediction of the phototoxic potentials of fluoroquinolones.	2001 Dec	11698174
[Effect of subinhibitory levels of aminoglycosides and fluoroquinolines on hydrophobicity and motility of Serratia marcescens].	2001 Feb	11233670
[Observations of properties of the L-form of M. tuberculosis induced by the antituberculosis drugs].	2001 Jan	11802941
Dental health and viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients.	2001 Mar	11313689
Antimicrobial resistance of Enterococci in Lebanon.	2001 Mar	11282266
Effect of disintegrants with different hygroscopicity on dissolution of Norfloxacin/Pharmatose DCL 11 tablets.	2001 Mar 23	11274814
Derivative spectrophotometric analysis of 4-quinolone antibacterials in formulations and spiked biological fluids by their Cu(II) complexes.	2001 Mar-Apr	11324600
Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents.	2001 May 15	11317264
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
[Bilateral serous retinal detachments in acute posterior multifocal placoid pigmentous epitheliopathy].	2001 Nov	11715108
New pyridoquinoline derivatives as potential inhibitors of the fluoroquinolone efflux pump in resistant Enterobacter aerogenes strains.	2001 Nov 8	11689091
Synthesis and antibacterial activity of some novel N-substituted piperazinyl-quinolones.	2001 Nov-Dec	11822230
Studies on the uptake and release of fluoroquinolones by disposable contact lenses.	2001 Oct	11725985
Treatment of malignant biliary stenosis: which stent to use?	2001 Oct-Dec	11887633
In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.	2002 Feb	11858908
Activation of phagocytic cell NADPH oxidase by norfloxacin: a potential mechanism to explain its bactericidal action.	2002 Feb	11818446
Influence of CO(2) incubation on quinolone activity against Streptococcus pneumoniae and Haemophilus influenzae.	2002 Jan	11821174
[Urinary infections without complications: comparison of a treatment with norfloxacin for 7 days versus norfloxacin for 3 days].	2002 Jan	11820968
Treatment of acute bacterial conjunctivitis with topical netilmicin.	2002 Jan	11805506

Patents

Sample Use Guides

In Vivo Use Guide

Norfloxacin tablets is administered orally with a glass of water at least 1 hour before or at least 2 hours after a meal or dairy products (e.g., milk, yogurt). Patients receiving norfloxacin should be well hydrated and should be instructed to drink fluids liberally. The maximal oral dose is 400 mg. For treatment of conjunctivitus, norfloxacin should be instilled at 1 or 2 drops to the affected eye(s) 4 times daily for up to 7 days.

Route of Administration: Other

In Vitro Use Guide

Minimal inhibition concnetration of norfloxacin aganis S.aureus, E.coli and P.aeuginosa was determined using agar media by means of a standard twofold serial dilution method and comprised 0.39, 0.05 and 0.39 ug/mL correspondingly.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:32:18 UTC 2023` Edited by `admin` on `Wed Jul 05 22:32:18 UTC 2023`
Record UNII	N0F8P22L1P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NORFLOXACIN

Official Name

English

NORFLOXACIN [USP IMPURITY]

Common Name

English

NORFLOXACIN [MI]

Common Name

English

NORFLOXACIN [VANDF]

Common Name

English

NSC-757250

Code

English

NORFLOXACIN [EP MONOGRAPH]

Common Name

English

NORFLOXACIN [USP-RS]

Common Name

English

MK-366

Code

English

NOROXIN

Brand Name

English

NORFLOXACIN [USAN]

Common Name

English

norfloxacin [INN]

Common Name

English

NORFLOXACIN [MART.]

Common Name

English

CHIBROXIN

Brand Name

English

3-QUINOLINECARBOXYLIC ACID, 1-ETHYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-

Common Name

English

Norfloxacin [WHO-DD]

Common Name

English

NORFLOXACIN [ORANGE BOOK]

Common Name

English

1-ETHYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-3-QUINOLINE CARBOXYLIC ACID

Systematic Name

English

NORFLOXACIN [JAN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QS01AE02